Furthermore, theranostic paradigms, exemplified by radiolabelled prostate-specific membrane antigen (PSMA) ligands in prostate cancer, epitomize the exquisite precision of radiopharmaceuticals [109]. This evidence concerns the gene FOLH1 and prostate carcinoma.